Dedicated to Helping People Survive Cancer Powered by a passion to effect dramatic improvements in cancer survival rates, NanoCytomics team members are developing novel, highly accurate, low-cost, non-invasive tests for use in primary care physicians offices. The company intends to revolutionize the risk stratification of patients, helping physicians identify those likely to benefit from gold-standard diagnostic procedures as early as possible, when cancer treatments can be the most effective. NanoCytomics anticipates offering its first commercially available Laboratory Developed Test (LDT) for cancer risk stratification in Q4 2016.